

Prescribing Clinical Network

<b>Policy Statement</b>	Sarilumab for moderate to severe of rheumatoid arthritis (NICE TA485)
<b>Policy No:</b>	PCN 299- 2017
<b>Date of Issue</b>	December - 2017
<b>Review Date:</b>	December - 2020 <i>(Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)</i>
<p><b>Recommendations:</b> The PCN recommends Sarilumab as a treatment option for the treatment of moderate to severe Rheumatoid Arthritis in line with NICE TA485</p> <p>Prescribing will be by hospital specialists only, in line with NICE TA485 using Blueteq initiation and continuation forms. Sarilumab will be considered <b>RED</b> on the traffic light system</p>	
<p><b>Key Considerations:</b></p> <ul style="list-style-type: none"> <li>NICE TA485 Sarilumab for moderate to severe rheumatoid arthritis <a href="https://www.nice.org.uk/guidance/ta485/resources/sarilumab-for-moderate-to-severe-rheumatoid-arthritis-pdf-82605028168645">https://www.nice.org.uk/guidance/ta485/resources/sarilumab-for-moderate-to-severe-rheumatoid-arthritis-pdf-82605028168645</a></li> </ul>	
<b>Date taken to Prescribing Clinical Network</b>	6 <sup>th</sup> December 2017
<b>Agreed by PCN members</b>	18 <sup>th</sup> December 2017

Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG), Crawley CCG and Horsham & Mid-Sussex CCG